1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Epigenetic Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Epigenetic Drugs Market, by Deployment Model
8.1.1. On-premise (perpetual / licensed)
8.1.1.1. Market Revenue and Forecast
8.1.2. Subscription / Floating licenses
8.1.2.1. Market Revenue and Forecast
8.1.3. Cloud-native SaaS / Pay-per-use
8.1.3.1. Market Revenue and Forecast
8.1.4. Hybrid (cloud + on-prem)
8.1.4.1. Market Revenue and Forecast
8.1.5. Other
8.1.5.1. Market Revenue and Forecast
9.1. Epigenetic Drugs Market, by End-User Industry
9.1.1. Semiconductor & Fabless IC Design Houses
9.1.1.1. Market Revenue and Forecast
9.1.2. Electronic Systems OEMs
9.1.2.1. Market Revenue and Forecast
9.1.3. Foundries & IDM
9.1.3.1. Market Revenue and Forecast
9.1.4. PCB & EMS providers
9.1.4.1. Market Revenue and Forecast
9.1.5. Academic & Research
9.1.5.1. Market Revenue and Forecast
9.1.6. Government / Defense / Aerospace
9.1.6.1. Market Revenue and Forecast
10.1. Epigenetic Drugs Market, by Application / Use Case
10.1.1. ASIC / SoC Design
10.1.1.1. Market Revenue and Forecast
10.1.2. FPGA Design & Toolchains
10.1.2.1. Market Revenue and Forecast
10.1.3. PCB & Board-level Design
10.1.3.1. Market Revenue and Forecast
10.1.4. Package / Substrate Co-design
10.1.4.1. Market Revenue and Forecast
10.1.5. System-level & Multi-discipline (SI/PI, thermal)
10.1.5.1. Market Revenue and Forecast
10.1.6. MEMS & Sensor design
10.1.6.1. Market Revenue and Forecast
10.1.7. Power & Thermal analysis
10.1.7.1. Market Revenue and Forecast
10.1.8. Other
10.1.8.1. Market Revenue and Forecast
11.1. Epigenetic Drugs Market, by Sales Channel / GTM
11.1.1. Direct enterprise sales
11.1.1.1. Market Revenue and Forecast
11.1.2. Channel / Value-added resellers
11.1.2.1. Market Revenue and Forecast
11.1.3. Online / Self-serve / App-store sales
11.1.3.1. Market Revenue and Forecast
11.1.4. OEM bundling / ISV partnerships
11.1.4.1. Market Revenue and Forecast
11.1.5. Other
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Deployment Model
12.1.2. Market Revenue and Forecast, by End-User Industry
12.1.3. Market Revenue and Forecast, by Application / Use Case
12.1.4. Market Revenue and Forecast, by Sales Channel / GTM
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Deployment Model
12.1.5.2. Market Revenue and Forecast, by End-User Industry
12.1.5.3. Market Revenue and Forecast, by Application / Use Case
12.1.5.4. Market Revenue and Forecast, by Sales Channel / GTM
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Deployment Model
12.1.6.2. Market Revenue and Forecast, by End-User Industry
12.1.6.3. Market Revenue and Forecast, by Application / Use Case
12.1.6.4. Market Revenue and Forecast, by Sales Channel / GTM
12.2. Europe
12.2.1. Market Revenue and Forecast, by Deployment Model
12.2.2. Market Revenue and Forecast, by End-User Industry
12.2.3. Market Revenue and Forecast, by Application / Use Case
12.2.4. Market Revenue and Forecast, by Sales Channel / GTM
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Deployment Model
12.2.5.2. Market Revenue and Forecast, by End-User Industry
12.2.5.3. Market Revenue and Forecast, by Application / Use Case
12.2.5.4. Market Revenue and Forecast, by Sales Channel / GTM
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Deployment Model
12.2.6.2. Market Revenue and Forecast, by End-User Industry
12.2.6.3. Market Revenue and Forecast, by Application / Use Case
12.2.6.4. Market Revenue and Forecast, by Sales Channel / GTM
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Deployment Model
12.2.7.2. Market Revenue and Forecast, by End-User Industry
12.2.7.3. Market Revenue and Forecast, by Application / Use Case
12.2.7.4. Market Revenue and Forecast, by Sales Channel / GTM
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Deployment Model
12.2.8.2. Market Revenue and Forecast, by End-User Industry
12.2.8.3. Market Revenue and Forecast, by Application / Use Case
12.2.8.4. Market Revenue and Forecast, by Sales Channel / GTM
12.3. APAC
12.3.1. Market Revenue and Forecast, by Deployment Model
12.3.2. Market Revenue and Forecast, by End-User Industry
12.3.3. Market Revenue and Forecast, by Application / Use Case
12.3.4. Market Revenue and Forecast, by Sales Channel / GTM
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Deployment Model
12.3.5.2. Market Revenue and Forecast, by End-User Industry
12.3.5.3. Market Revenue and Forecast, by Application / Use Case
12.3.5.4. Market Revenue and Forecast, by Sales Channel / GTM
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Deployment Model
12.3.6.2. Market Revenue and Forecast, by End-User Industry
12.3.6.3. Market Revenue and Forecast, by Application / Use Case
12.3.6.4. Market Revenue and Forecast, by Sales Channel / GTM
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Deployment Model
12.3.7.2. Market Revenue and Forecast, by End-User Industry
12.3.7.3. Market Revenue and Forecast, by Application / Use Case
12.3.7.4. Market Revenue and Forecast, by Sales Channel / GTM
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Deployment Model
12.3.8.2. Market Revenue and Forecast, by End-User Industry
12.3.8.3. Market Revenue and Forecast, by Application / Use Case
12.3.8.4. Market Revenue and Forecast, by Sales Channel / GTM
12.4. MEA
12.4.1. Market Revenue and Forecast, by Deployment Model
12.4.2. Market Revenue and Forecast, by End-User Industry
12.4.3. Market Revenue and Forecast, by Application / Use Case
12.4.4. Market Revenue and Forecast, by Sales Channel / GTM
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Deployment Model
12.4.5.2. Market Revenue and Forecast, by End-User Industry
12.4.5.3. Market Revenue and Forecast, by Application / Use Case
12.4.5.4. Market Revenue and Forecast, by Sales Channel / GTM
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Deployment Model
12.4.6.2. Market Revenue and Forecast, by End-User Industry
12.4.6.3. Market Revenue and Forecast, by Application / Use Case
12.4.6.4. Market Revenue and Forecast, by Sales Channel / GTM
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Deployment Model
12.4.7.2. Market Revenue and Forecast, by End-User Industry
12.4.7.3. Market Revenue and Forecast, by Application / Use Case
12.4.7.4. Market Revenue and Forecast, by Sales Channel / GTM
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Deployment Model
12.4.8.2. Market Revenue and Forecast, by End-User Industry
12.4.8.3. Market Revenue and Forecast, by Application / Use Case
12.4.8.4. Market Revenue and Forecast, by Sales Channel / GTM
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Deployment Model
12.5.2. Market Revenue and Forecast, by End-User Industry
12.5.3. Market Revenue and Forecast, by Application / Use Case
12.5.4. Market Revenue and Forecast, by Sales Channel / GTM
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Deployment Model
12.5.5.2. Market Revenue and Forecast, by End-User Industry
12.5.5.3. Market Revenue and Forecast, by Application / Use Case
12.5.5.4. Market Revenue and Forecast, by Sales Channel / GTM
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Deployment Model
12.5.6.2. Market Revenue and Forecast, by End-User Industry
12.5.6.3. Market Revenue and Forecast, by Application / Use Case
12.5.6.4. Market Revenue and Forecast, by Sales Channel / GTM
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Celgene Corporation
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck & Co
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Eisai Co., Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GlaxoSmithKline plc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AstraZeneca plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Chroma Therapeutics
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Syndax Pharmaceuticals
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Mirati Therapeutics
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Abbott
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
